In a video interview from the recent American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium, Brian Chapin, MD, discussed emerging research that demonstrated the ability of the positron emission tomography (PET) agent 18F-rhPSMA-7.3 to diagnose distant M1 lesions prior to surgery for patients with intermediate to high-risk prostate cancer.
Conventional imaging can be limited in the detection of metastatic lesions associated with prostate cancer. Specificity rates for computed tomography (CT) are “reportedly all over the map,” ranging from 40 to 60 percent, pointed out Brian Chapin, MD, in a video interview from the recent American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) symposium.
“When there is lymph node involvement … , the lymph nodes themselves can be small and the deposits within those lymph nodes can be as small as 1 to 3 mm in size sometimes so it’s really hard to identify those with a conventional imaging approach,” explained Dr. Chapin, an associate professor, director of clinical research and fellowship program director in the Department of Urology within the Division of Surgery at the University of Texas MD Anderson Cancer Center in Houston.
However, in recent research presented at the ASCO GU symposium, Dr. Chapin and colleagues found the use of the radiopharmaceutical agent 18F-rhPSMA-7.3 (Blue Earth Diagnostics/Bracco Imaging) with positron emission tomography (PET) led to verified detection of distant metastatic lesions in 10 to 15 percent of 335 patients with newly diagnosed intermediate or high-risk prostate cancer.
“One in 10 patients that we had planned to bring to the operating room with presumed localized prostate cancer indeed had metastatic disease, which is quite substantial, especially when you’re looking at a population of men who had (negative conventional imaging with CT, MRI and bone scan),” emphasized Dr. Chapin. “Those were all negative and you’re identifying metastatic disease in one in 10 patients. That is pretty substantial because that can change our clinical decision-making in how we treat patients.”
(Editor’s note: For related content, see “Study Assesses PET Agent for Detecting Pelvic Lymph Node Metastases in Patients with Prostate Cancer,” “Could an Emerging PSMA/PET Imaging Agent Improve the Detection of Recurrent Prostate Cancer?” and “Is PSMA PET/CT More Beneficial than Bone Scintigraphy in Detecting Bone Lesions in Cases of High-Risk Prostate Cancer?”)
For more insights from Dr. Chapin, watch the video below.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
CT Perfusion Study Shows Enhanced Detection of Medium Vessel Occlusions with Emerging AI Software
May 21st 2025The Rapid CTP AI software offered 23 percent greater detection of medium vessel occlusions in comparison to the Viz CTP AI software, according to research presented at the European Stroke (Organization) Conference (ESOC).
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.